Dr Donna Culton walks through the pathophysiology of type 2 inflammation in inflammatory skin diseases, using bullous pemphigoid as an example. Drs Eichenfield, Elmariah, and Hawkes join to discuss the role of type 2 inflammation across atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria, respectively.
Follow Janet, a hypothetical patient, as she navigates the difficult journey of bullous pemphigoid, starting with symptom onset to diagnosis.
A static infographic detailing how autoimmunity and Type 2 inflammation play a critical role in the pathophysiology of Bullous Pemphigoid (BP).

Dr. Donna Culton describes the heterogeneous presentation and diagnosis of bullous pemphigoid at EADV 2025

Dr. Donna Culton discusses the elevated mortality risk in patients with bullous pemphigoid at EADV 2025
Professor Dédée Murrell highlights the importance of early diagnosis in bullous pemphigoid at EADV 2025

This interactive tool systematically guides healthcare providers through the complete diagnostic pathway for suspected bullous pemphigoid and provides a comparative overview of leading international treatment guidelines to inform optimal patient management.
Dr Sarina Elmariah highlights the clinical challenges in diagnosing inflammatory skin diseases, using prurigo nodularis as a case study. Drs Culton, Eichenfield, and Hawkes then join in to discuss additional challenges and complexities when diagnosing other skin diseases.
Experience this engaging presentation by Dr. Donna Culton, Prof. Dédée Murrell, and Prof. Ulrike Raap, who highlight the heterogeneous clinical presentations of BP and its burden, delve beneath the surface into how autoimmunity and predominantly type 2 inflammation mediate the disease, and explore the evolving toolbox of current approaches in BP management.
Watch Dr. Donna Culton, Prof. Dédée Murrell, and Prof. Ulrike Raap at EADV 2025 as they explore the clinical presentation and diagnosis of BP and break down the underlying pathophysiology including the roles of autoimmunity and key inflammatory pathways such as Type 2 inflammation. The experts also discuss the evolving therapeutic landscape and how new insights are shaping future treatment strategies.

Welcome to the BP learning hub focused on key scientific education on bullous pemphigoid, featuring ADVENT resources.

Join Dr. Werth as she outlines how early diagnosis and treatment are critical to minimize risk and improve long term outcomes in patients with BP.